Cell Therapy Catapult & University of Leeds to collaborate on acellular scaffolds

February 24, 2014
Access to expertise at two of University’s centres
The Cell Therapy Catapult, which is focused on the development of the UK cell therapy industry to increase the nation’s health and wealth, and the University of Leeds have agreed to work together on acellular scaffolds for the delivery of cellular therapies. The University’s Regener8 (the N8 Centre for Translational Regenerative Medicine) and Medical Technologies Innovation and Knowledge Centre have extensive expertise in regenerative devices, scaffolds and biomaterials, which are pivotal to the development of new cell therapies.
The two centres and the Cell Therapy Catapult are looking to identify projects, including those from the University’s research base and project teams supported by Regener8 funding, which they can develop further together. Areas of expertise at Regener8 and the Medical Technologies IKC include hard and soft tissue repair using acellular scaffolds as well as other delivery technologies for regenerative medicines. There is also a focus on supporting high-value manufacturing companies.
Keith Thompson, CEO of the Cell Therapy Catapult, said, ‘This agreement is a further recognition of the calibre of the cell therapy research base in UK academia, and we are delighted to be working with the University of Leeds. At the Cell Therapy Catapult we recognise the need to access a range of scaffolds to support cell therapy projects, and the expertise in Leeds will complement the portfolio that we are developing.’
Dr Mike Raxworthy, Operations Director of Regener8, said, ‘Our emphasis is to encourage the translation of university and industry research in regenerative medicine into commercial products and clinical benefits. We bring together world-leading scientists from the N8 universities with industry and are delighted to extend this to partnership to the Cell Therapy Catapult in the valuable work it is undertaking.’
Professor John Fisher, CBE, Executive Director of Regener8, Medical Technologies IKC & Director of the Institute of Medical and Biological Engineering, University of Leeds said, ‘We welcome this agreement to collaborate, leveraging our capabilities in regenerative devices, biomaterials and tissue scaffolds. Coupled with our research excellence in medical engineering, preclinical simulation and medical device manufacturing, we can provide complementary research and training to support the translational activity at the Cell Therapy Catapult.’
- July 2019
- February 2019
- December 2018
- November 2018
- October 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- June 2017
- May 2017
- March 2017
- February 2017
- January 2017
- November 2016
- October 2016
- September 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- September 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- October 2013
- September 2013
- February 2013